The ENERGY Study: An Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INZ-701 in Infants with Ectonucleotide Pyrophosphatase/ Phosphodiesterase 1 (ENPP1) Deficiency or ATP-binding Cassette Sub-family C Member 6 (ABCC6) Deficiency
The ENERGY study is investigating a new medicine called INZ-701 for infants (very young children) who have one of two rare genetic conditions. These conditions are sometimes called ENPP1 deficiency or ABCC6 deficiency. The main goal of this study is to find out if INZ-701 is safe for these children and to understand how their bodies react to the medicine. Researchers will be carefully checking for any side effects, observing vital signs like heart rate and weight, and performing blood and urine tests. They also want to see how the medicine moves through the body and assess its potential effects on the condition itself. This is an early-stage study, meaning it's one of the first times this medicine is being tested in humans.
Auf einen Blick
Worum geht es in dieser Studie?
The ENERGY study is a research project focusing on a new medicine, INZ-701, for infants diagnosed with very specific genetic conditions. These conditions are quite rare and can affect different parts of the body. The scientific names for these conditions are Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency and ATP-binding Cassette Sub-family C Member 6 (ABCC6) Deficiency. Because these names are long and complicated, it's easier to think of them as rare genetic problems that doctors are trying to understand and treat better.
In this study, doctors want to learn several important things about INZ-701. Firstly, they need to know if the medicine is safe for young children with these conditions. They will be looking very closely for any unwanted effects, often called side effects. Secondly, they want to understand how the medicine works in the body – for example, how much of it stays in the blood and for how long. This helps them figure out the best way to give the medicine in the future. They will also look at whether the medicine has any effect on certain markers related to the conditions.
This type of study is called a 'Phase I' study, which means it's one of the earliest steps in testing a new medicine in people. It's a key stage before a medicine can move on to larger studies to see how well it works. By carefully collecting information on safety, how the body handles the medicine, and early signs of its effects, researchers can decide if INZ-701 has the potential to help children with these rare conditions.
Wichtige Erkenntnisse
- This study is testing a new medicine (INZ-701) for infants with rare genetic conditions.
- Die Hauptziele sind, die Sicherheit des Medikaments zu überprüfen und wie der Körper damit umgeht.
- It's an early-stage study, meaning it's one of the first times it's being tested in people.
- Participation involves regular clinic visits, blood tests, and heart checks.
- Both boys and girls with these specific conditions are eligible.
- Sie können Ihr Kind jederzeit von der Studie zurückziehen.
Wer könnte berechtigt sein?
This study is specifically for infants (babies) who have been diagnosed with one of two rare genetic conditions: ENPP1 deficiency or ABCC6 deficiency.
To be considered for the study, your baby's doctor would need to confirm that they have one of these specific conditions. There are no age limits within the 'infant' category, so babies of various ages could potentially be included.
Both boys and girls can take part in this study, assuming they meet the other requirements related to their specific medical condition.
Könnte diese Studie für Sie geeignet sein?
Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.
- Is your child an infant (baby)?
- Has your child been diagnosed with ENPP1 deficiency?
- OR has your child been diagnosed with ABCC6 deficiency?
- Are you able to attend regular hospital or clinic visits?
Was beinhaltet die Teilnahme?
If your child takes part in the ENERGY study, they would receive the study medicine, INZ-701. Participation would involve regular visits to the clinic or hospital. During these visits, there would be various assessments to check your child's health and how they are reacting to the medicine. These would include checking their vital signs (like heart rate and breathing), taking their weight, and collecting blood and urine samples for tests. Doctors would also monitor their heart using specific scans (like an ultrasound of the heart called an echocardiogram and an electrocardiogram, which checks the electrical activity of the heart).
The study would also involve keeping track of any other medicines your child is taking and carefully noting any side effects or changes in their health. The information gathered, especially about how the medicine is absorbed and leaves the body, would be collected over regular intervals for up to a year (52 weeks). There will be a detailed schedule of visits and tests over this entire period.
Potenzielle Risiken und Vorteile
Standorte (1)
- —UnbestätigtSpanien
Häufige Fragen
What is a 'genetic deficiency'?
A genetic deficiency means that there's a small change in a child's genes that causes their body not to make enough of a certain important protein or chemical.
Is this medicine available to everyone?
No, INZ-701 is an experimental medicine, which means it's still being studied and is not yet available as a regular treatment.
What does 'open-label' mean?
It means that both you and the doctors involved in the study will know that your child is receiving the study medicine, INZ-701.
Was passiert, nachdem die Studie endet?
At the end of the study, your child's doctors will discuss the next steps for their care. The study aims to gather information, not necessarily provide long-term treatment.
Will my child feel any pain?
Some procedures, like blood tests, involve minor discomfort. The study team will always try to make your child as comfortable as possible and explain everything beforehand.
Wie Sie mehr erfahren können
Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.
Interessiert daran, teilzunehmen?
Diskussion
Community-Diskussion
Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.